Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: May 23, 2025
Principal Executive Office: Marseille, France
Context: This filing serves as a cover document for a press release dated May 23, 2025 (Exhibit 1.1). The text provided contains only the cover page and signature block; the content of the press release is not included in the source text.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods. The specific nature of the announcement referenced in Exhibit 1.1 is not described in the cover document.
Guidance, Outlook, and Risks
The provided text does not include management commentary, forward-looking guidance, risk factors, contingencies, or details on unusual items. These elements would be contained within the referenced press release (Exhibit 1.1), which is not part of the input text.
Investor Verification Checklist
- Verify the content of the press release dated May 23, 2025 (Exhibit 1.1) to understand the specific event triggering this filing.
- Review the company's most recent Form 20-F or quarterly reports for the latest audited financial metrics, as this 6-K does not contain them.
- Confirm if the press release contains material updates to clinical trial progress, regulatory approvals, or partnership agreements, which are typical for this biopharmaceutical issuer.